SPY336.11+1.22 0.36%
DIA277.33-0.17 -0.06%
IXIC11,301.38+133.87 1.20%

Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease, Expects to Announce Top-Line Results in Q4

Benzinga · 08/24/2020 10:53